
**Ophthalmic implants — Intraocular
lenses —**

**Part 5:
Biocompatibility**

*Implants ophtalmiques — Lentilles intraoculaires —
Partie 5: Biocompatibilité*

**iTeh STANDARD PREVIEW
(standards.iteh.ai)**

[ISO 11979-5:2006](https://standards.iteh.ai/catalog/standards/sist/80acc053-9f55-4a61-b97b-ca01b992a3d0/iso-11979-5-2006)

[https://standards.iteh.ai/catalog/standards/sist/80acc053-9f55-4a61-b97b-
ca01b992a3d0/iso-11979-5-2006](https://standards.iteh.ai/catalog/standards/sist/80acc053-9f55-4a61-b97b-ca01b992a3d0/iso-11979-5-2006)



PDF disclaimer

This PDF file may contain embedded typefaces. In accordance with Adobe's licensing policy, this file may be printed or viewed but shall not be edited unless the typefaces which are embedded are licensed to and installed on the computer performing the editing. In downloading this file, parties accept therein the responsibility of not infringing Adobe's licensing policy. The ISO Central Secretariat accepts no liability in this area.

Adobe is a trademark of Adobe Systems Incorporated.

Details of the software products used to create this PDF file can be found in the General Info relative to the file; the PDF-creation parameters were optimized for printing. Every care has been taken to ensure that the file is suitable for use by ISO member bodies. In the unlikely event that a problem relating to it is found, please inform the Central Secretariat at the address given below.

iTeh STANDARD PREVIEW
(standards.iteh.ai)

[ISO 11979-5:2006](#)

<https://standards.iteh.ai/catalog/standards/sist/80acc053-9f55-4a61-b97b-ca01b992a3d0/iso-11979-5-2006>

© ISO 2006

All rights reserved. Unless otherwise specified, no part of this publication may be reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying and microfilm, without permission in writing from either ISO at the address below or ISO's member body in the country of the requester.

ISO copyright office
Case postale 56 • CH-1211 Geneva 20
Tel. + 41 22 749 01 11
Fax + 41 22 749 09 47
E-mail copyright@iso.org
Web www.iso.org

Published in Switzerland

Contents

Page

Foreword	iv
Introduction	v
1 Scope	1
2 Normative references	1
3 Terms and definitions	1
4 General requirements applying to biocompatibility evaluation of intraocular lenses	2
5 Physicochemical tests	2
6 Biological tests	5
Annex A (normative) Exhaustive extraction test	7
Annex B (normative) Test for leachables	10
Annex C (normative) Hydrolytic stability	12
Annex D (normative) Photostability test	15
Annex E (normative) Nd-YAG laser exposure test	17
Annex F (informative) Supplemental conditions of test for local effects after implantation	19
Annex G (normative) Ocular implantation test	20
Bibliography	24

<https://standards.iteh.ai/catalog/standards/sist/80acc053-9155-4a61-b97b-ca01b992a3d0/iso-11979-5-2006>

Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

International Standards are drafted in accordance with the rules given in the ISO/IEC Directives, Part 2.

The main task of technical committees is to prepare International Standards. Draft International Standards adopted by the technical committees are circulated to the member bodies for voting. Publication as an International Standard requires approval by at least 75 % of the member bodies casting a vote.

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights.

ISO 11979-5 was prepared by Technical Committee ISO/TC 172, *Optics and photonics*, Subcommittee SC 7, *Ophthalmic optics and instruments*.

This second edition cancels and replaces the first edition (ISO 11979-5:1999), which has been technically revised.

ISO 11979 consists of the following parts, under the general title *Ophthalmic implants — Intraocular lenses*:

- *Part 1: Vocabulary* <https://standards.iteh.ai/catalog/standards/sist/80acc053-9f55-4a61-b97b-ca01b992a3d0/iso-11979-5-2006>
- *Part 2: Optical properties and test methods*
- *Part 3: Mechanical properties and test methods*
- *Part 4: Labelling and information*
- *Part 5: Biocompatibility*
- *Part 6: Shelf-life and transport stability*
- *Part 7: Clinical investigations*
- *Part 8: Fundamental requirements*
- *Part 9: Multifocal intraocular lenses*
- *Part 10: Phakic intraocular lenses*

Introduction

This part of ISO 11979 follows the general principles given in ISO 10993-1. ISO 10993-1 describes the principles governing the biological evaluation of medical devices, the definitions of categories based on the nature and duration of contact with the body, and selection of appropriate tests. Other parts of ISO 10993 present biological test methods, tests for ethylene oxide residues, tests for degradation and principles for sample preparation.

iTeh STANDARD PREVIEW (standards.iteh.ai)

[ISO 11979-5:2006](https://standards.iteh.ai/catalog/standards/sist/80acc053-9f55-4a61-b97b-ca01b992a3d0/iso-11979-5-2006)

<https://standards.iteh.ai/catalog/standards/sist/80acc053-9f55-4a61-b97b-ca01b992a3d0/iso-11979-5-2006>

iTeh STANDARD PREVIEW
(standards.iteh.ai)

[ISO 11979-5:2006](https://standards.iteh.ai/catalog/standards/sist/80acc053-9f55-4a61-b97b-ca01b992a3d0/iso-11979-5-2006)

<https://standards.iteh.ai/catalog/standards/sist/80acc053-9f55-4a61-b97b-ca01b992a3d0/iso-11979-5-2006>

Ophthalmic implants — Intraocular lenses —

Part 5: Biocompatibility

1 Scope

This part of ISO 11979 specifies particular requirements for the biocompatibility evaluation of materials for intraocular lenses (IOLs) including the processing conditions to produce them. These requirements include evaluation of physicochemical properties that are relevant to biocompatibility. It also gives guidance on conducting an ocular implantation test.

2 Normative references

The following referenced documents are indispensable for the application of this document. For dated references, only the edition cited applies. For undated references, the latest edition of the referenced document (including any amendments) applies.

ISO 10993-1, *Biological evaluation of medical devices — Part 1: Evaluation and testing*

ISO 10993-2, *Biological evaluation of medical devices — Part 2: Animal welfare requirements*

ISO 10993-3, *Biological evaluation of medical devices — Part 3: Tests for genotoxicity, carcinogenicity and reproductive toxicity*

ISO 10993-6, *Biological evaluation of medical devices — Part 6: Tests for local effects after implantation*

ISO 10993-10, *Biological evaluation of medical devices — Part 10: Tests for irritation and delayed-type hypersensitivity*

ISO 10993-12, *Biological evaluation of medical devices — Part 12: Sample preparation and reference materials*

ISO 11979-1, *Ophthalmic implants — Intraocular lenses — Part 1: Vocabulary*

ISO 11979-2, *Ophthalmic implants — Intraocular lenses — Part 2: Optical properties and test methods*

ISO 11979-3, *Ophthalmic implants — Intraocular lenses — Part 3: Mechanical properties and test methods*

ISO 14971, *Medical devices — Application of risk management to medical devices*

3 Terms and definitions

For the purposes of this document, the terms and definitions given in ISO 11979-1 apply.

4 General requirements applying to biocompatibility evaluation of intraocular lenses

The evaluation of the biocompatibility of the test material shall start with an initial assessment of risk in accordance with ISO 14971. The physicochemical tests described in Clause 5 shall first be considered. The evaluation of the material for biological safety shall then be undertaken in accordance with the principles and requirements of ISO 10993-1 and ISO 10993-2, taking into consideration the results from the physicochemical tests.

Furthermore, the risk assessment shall include an assessment of the potential for material changes such as calcification. This risk assessment should consider the history of clinical use of the material, and animal models to test the long-term stability of the material.

Carry out the biocompatibility testing in accordance with ISO 10993-1, ISO 10993-3, ISO 10993-5, ISO 10993-6 and ISO 10993-10 and as noted in this part of ISO 11979.

The pre-existing information on the material and all the information obtained in the evaluation process shall be integrated in an overall risk benefit assessment in accordance with ISO 14971.

5 Physicochemical tests

5.1 General

5.1.1 The following physicochemical tests shall be considered:

- a) exhaustive extraction;
- b) leachables;
- c) hydrolytic stability;
- d) photostability against ultraviolet/visible (UV/Vis) irradiation;
- e) stability against Nd-YAG laser exposure;
- f) insoluble inorganics.

ITeH STANDARD PREVIEW
(standards.iteh.ai)
<https://standards.iteh.ai/catalog/standards/sist/80acc053-9f55-4a61-b97b-ca01b992a3d0/iso-11979-5-2006>
ISO 11979-5:2006

5.1.2 The objectives of this group of tests are:

- a) to quantify possible residues from synthesis and additives or impurities from manufacturing and packaging;
- b) to quantify possible degradation products due to hydrolysis;
- c) to quantify leachable chemical components; and
- d) to facilitate an analysis of any risks introduced by toxic products which may result from processing, treatment in use, or ageing of the test material.

5.1.3 The results of the tests given in 5.1.1 and 5.1.2 shall be recorded and included in the assessment for risk in accordance with ISO 14971. If any of the above tests was not performed, a rationale justifying this decision shall be documented.

5.2 Exhaustive extraction test

The test material shall be tested for extractables under exhaustive extraction conditions in accordance with the method described in Annex A, which describes several extraction conditions, including the extraction media, temperature and duration. Alternate methods can be used provided that they have been validated.

The following shall be observed.

- a) The reasons for selecting each solvent shall be justified and documented.
- b) The extraction media shall be qualitatively and quantitatively analysed at the end of extraction for possible extractable components of the material, such as process contaminants, residual monomers, additives, and other extractable components. The detection limit for the extractables shall be established based on a risk assessment of the total exposure to the patient and it shall be expressed as µg/g of material.
- c) The test material shall be weighed before and after extraction and any change in mass shall be calculated.

The results shall be evaluated to assess the risk for potentially harmful effects due to extractable components and they shall be recorded.

5.3 Test for leachables

The test material shall be tested for leachables under simulated physiological conditions in accordance with the method described in Annex B, which specifies several extraction conditions including the extraction media, temperature and duration.

The following shall be observed.

- a) The reasons for selecting each solvent shall be justified and documented.
- b) The extraction media shall be qualitatively and quantitatively analysed at the end of extraction for possible extractable components of the material, such as process contaminants, residual monomers, additives, and other extractable components. The detection limit for the extractables shall be established based on a risk assessment of the total exposure to the patient and it shall be expressed as µg/g of material.

The results shall be evaluated to assess the risk for potentially harmful effects from extractable components and they shall be recorded.

5.4 Test for hydrolytic stability

Hydrolytic stability testing shall be conducted in accordance with the method described in Annex C. The following shall be observed.

- a) The study shall be designed to evaluate the stability of the material in an aqueous environment at $35\text{ °C} \pm 2\text{ °C}$ for a period of at least five years or at an elevated temperature for a simulated exposure time of at least five years.
- b) The simulated exposure time is to be determined by multiplying the actual study time with the following factor F :

$$F = 2,0^{(T_a - T_0)/10}$$

where

T_a is the accelerated temperature;

T_0 is the temperature of the inside of the eye (35 °C).

- c) The exposure medium shall be qualitatively and quantitatively analysed for any chemical entities at the end of the exposure period.
- d) The test material shall be examined by light microscopy at 10× or higher and by scanning electron microscopy (SEM) at 500× or higher before and after testing. The test material shall be compared with the untreated material and there shall be no significant difference in surface appearance (e.g. bubbles, dendrites, breaks and fissures).
- e) Optical transmittance spectra of the test material in the ultraviolet and visible spectral regions (UV/Vis) shall be recorded before and after testing. By comparison of the spectra, assurance shall be obtained that there are no significant changes in spectral transmittance. The dioptric power shall be determined before and after testing if finished IOLs are used in the testing. The refractive index shall be determined instead if a facsimile material is used. There shall be no significant change in dioptric power ($\pm 0,25$ D for a 20 D lens) or refractive index before and after testing.

The results shall be evaluated to assess the risk for potentially harmful effects due to instability of the material in an aqueous environment and they shall be recorded.

5.5 Photostability test

Photostability testing shall be conducted in accordance with Annex D.

Furthermore, when performing the testing for anterior chamber IOLs, it shall be shown that no significant change in mechanical properties of the irradiated test material has occurred when compared with non-irradiated test material.

No significant change shall be detected between the UV/Vis spectra of the test material exposed to UV radiation and controls receiving no radiation.

NOTE 1 The loops of implanted anterior chamber IOLs are exposed to radiation, hence the rationale for requiring mechanical testing after irradiation.

NOTE 2 The following parameters have been found to be relevant to *in situ* exposure of an IOL to UV radiation:

- a) *in vivo* UV-A radiation intensity in the range 300 nm to 400 nm at the position of the IOL at diffuse light conditions (I_1): 0,3 mW/cm²;

The internationally accepted estimation for full intensity of sunlight is an average of 1 kW/m² = 100 mW/cm² in sunny areas close to the Tropic of Cancer. The portion of near ultraviolet wavelengths in the 300 nm to 400 nm range is approximately 6,5 % of the total intensity, i.e. about 6,5 mW/cm². Intraocular lenses are exposed to sunlight which reaches behind the cornea and the aqueous humour. Within the spectrum of sunlight, that part of the near ultraviolet radiation which is not absorbed by the cornea and the aqueous humour and which can potentially damage IOLs by photochemical degradation, amounts to approximately 40 % to 50 % of the total UV-A radiation. Assuming that the cornea and the aqueous humour absorb 50 % of the UV-A, the IOL is exposed to an irradiation of 3,25 mW/cm² in the 300 nm to 400 nm range at full intensity of sunlight. The diffuse, reflected light intensity is estimated to be one-tenth of the above value. The irradiation of an intraocular lens *in vivo* is therefore approximately 0,3 mW/cm².

- b) daily exposure time to sunlight (t): 3 h;
- c) *in vivo* exposure time (T_1): 20 years;
- d) intensity factor (n): 1 (i.e. maximum intensity under consideration of sunny regions).

The *in vitro* test period (T_2 , in days) can be calculated using the following equation (see Reference [1]), with (I_2) being the *in vitro* intensity of the radiation source in the 300 nm to 400 nm range,

$$T_2 = 365 \times T_1 \left[\left(\frac{I_2}{I_1} \right)^n \times \left(\frac{24}{t} \right) \right]^{-1}$$

EXAMPLE If $I_2 = 10$ mW/cm², $T_2 = 27,4$ d.

The results shall be evaluated to assess the risk of potential harmful effects due to degradation products identified in the photostability test and they shall be recorded.

5.6 Nd-YAG laser exposure test

The effect of Nd-YAG laser exposure shall be evaluated in accordance with Annex E.

There shall be no cytotoxic substances released due to Nd-YAG laser exposure.

5.7 Evaluation of insoluble inorganics

The IOL material shall be assessed for the presence of residual insoluble inorganics on and in the lens arising from manufacturing materials and process aids. Where possible residues have been identified, the lens shall be evaluated for such residuals. The test methods used for this evaluation shall be identified, validated and justified. Consideration shall be given to methods with a detection limit of 0,2 µg/lens or 10 µg/g, and in which the solvents will dissolve the material.

The results shall be evaluated to assess the risk of potentially harmful effects due to the presence of residual insoluble inorganics on and in the lens and they shall be recorded.

6 Biological tests

6.1 General

An evaluation of biological safety shall be undertaken in accordance with the principles and requirements of ISO 10993-1 taking into consideration the results of the physicochemical tests. The following biological endpoints shall be considered:

- the effects on cell growth and cell damage;
- genotoxicity;
- local effects after implantation;
- sensitization potential.

Where testing is deemed necessary, the appropriate parts of ISO 10993 shall apply. Supplements to these parts are described in 6.2 and 6.3. Sample preparation shall be performed in accordance with ISO 10993-12 taking into consideration the supplemental requirements. In addition, an ocular implantation test shall also be considered in accordance with 6.4.

If the risk assessment has identified the potential for material change when exposed to an *in vivo* environment, a test shall be performed to assess the reciprocal tolerance of the test material and local tissue. An example of such a test is the test for local effects after implantation as described in ISO 10993-6 supplemented as indicated in informative Annex F.

NOTE As the mass of an intraocular lens is typically only about 20 mg, in general no systemic or chronic toxicity testing is required.

6.2 Tests for genotoxicity

Testing for genotoxicity shall be performed in accordance with ISO 10993-3 supplemented with the following:

- Two separate extractions of the material shall be performed, one with physiological saline, and the other with a lipophilic or dipolar solvent. The lipophilic or dipolar solvent shall not dissolve or degrade the material.

- Extraction shall be performed with agitation at $37\text{ °C} \pm 2\text{ °C}$ for $72\text{ h} \pm 2\text{ h}$ at a ratio of 1 g of material per 10 ml of extracting medium.

6.3 Tests for sensitization

Testing for sensitization shall be performed in accordance with ISO 10993-10 supplemented with the following.

- Either the maximization sensitization test or the local lymph node assay (LLNA) can be used for testing.
- The test material shall be extracted with two different extractants, one of which is physiological saline, and the second a lipophilic or dipolar solvent. The lipophilic or dipolar solvent should not dissolve or degrade the test material. The solvent itself should also not be a known irritant, adjuvant or sensitizer.

6.4 Ocular implantation test

An intraocular implantation test shall be performed when the manufacturer has no documented evidence on the safety of the material in the intraocular environment. Testing shall be conducted in accordance with the general principles in ISO 10993-6, supplemented as described in Annex G. When this test is deemed not necessary, the risk assessment shall provide reasonable assurance that the risks arising from the new use of the material are deemed acceptable based on information from previous clinical use and other relevant literature.

iTeh STANDARD PREVIEW (standards.iteh.ai)

[ISO 11979-5:2006](https://standards.iteh.ai/catalog/standards/sist/80acc053-9f55-4a61-b97b-ca01b992a3d0/iso-11979-5-2006)

<https://standards.iteh.ai/catalog/standards/sist/80acc053-9f55-4a61-b97b-ca01b992a3d0/iso-11979-5-2006>